Definium Therapeutics (DFTX) Cash from Operations (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Cash from Operations data on file, last reported at 42631000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 44.91% year-over-year to 42631000.0 in Q1 2026; TTM through Mar 2026 was 144772000.0, a 57.45% decrease from a year earlier, with the FY2025 full-year figure at 131560000.0, down 66.26% from the prior year.
• Cash from Operations for Q1 2026 stood at 42631000.0, up from 42975000.0 in the prior quarter.
• Over the last five years, Cash from Operations for DFTX reached as high as 9297000.0 in Q3 2022 and fell as low as 42975000.0 in Q4 2025.
• Historically, Cash from Operations has averaged 21636705.88 across 5 years, with a median of 17191000.0 in 2024.
• Across the five-year window, Cash from Operations soared 44.6% in 2022 and tumbled 78.83% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 12849000.0 in 2022, then slumped by 60.04% to 20563000.0 in 2023, then dropped by 23.28% to 25351000.0 in 2024, then slumped by 69.52% to 42975000.0 in 2025, then gained by 0.8% to 42631000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 42631000.0 in Q1 2026, 42975000.0 in Q4 2025, and 29567000.0 in Q3 2025.